Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

PURPOSE: The AVAglio (Avastin in Glioblastoma) and RTOG-0825 randomized, placebo-controlled phase III trials in newly diagnosed glioblastoma reported prolonged progression-free survival (PFS), but not overall survival (OS), with the addition of bevacizumab to radiotherapy plus temozolomide. To estab...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Sandmann, Thomas, Bourgon, Richard, Garcia, Josep, Li, Congfen, Cloughesy, Timothy, Chinot, Olivier L., Wick, Wolfgang, Nishikawa, Ryo, Mason, Warren, Henriksson, Roger, Saran, Frank, Lai, Albert, Moore, Nicola, Kharbanda, Samir, Peale, Franklin, Hegde, Priti, Abrey, Lauren E., Phillips, Heidi S., Bais, Carlos
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5015426/
https://ncbi.nlm.nih.gov/pubmed/26124478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.61.5005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky